Loxo Oncology Inc. – NASDAQ:LOXO

Add to watchlist

234.76

+0.09

+0.04%

Market closed

Open in 25 minutes

+0.42%

month

+54.86%

quarter

+123.55%

year

Market Cap	6.57B
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-2.09

Revenue	124.97M
EBITDA	-64.11M
Income	-62.97M
Revenue Q/Q	3708.96%
Revenue Y/Y	5457.09%

Profit margin	-50.39%
Oper. margin	-58.31%
Gross margin	100%
EBIT margin	-58.31%
EBITDA margin	-51.3%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Profit Margin

Q Y

Loxo Oncology Inc. (NASDAQ:LOXO): Profit margin
Dec 2017	1.47M	-20.62M	-1394.73%
Mar 2018	38.42M	-3.55M	-9.26%
Jun 2018	42.60M	-11.72M	-27.53%
Sep 2018	42.47M	-27.06M	-63.72%

LOXO income statement history

Debt to Assets

Q Y

Loxo Oncology Inc. (NASDAQ:LOXO): Debt to assets
Dec 2017	783442000	405.23M	51.72%
Mar 2018	748609000	364.18M	48.65%
Jun 2018	716510000	324.38M	45.27%
Sep 2018	659228000	280.01M	42.48%

LOXO balance sheet history

Cash Flow

Q Y

Loxo Oncology Inc. (NASDAQ:LOXO): Cash Flow
Dec 2017	221.19M	-160.12M	533K
Mar 2018	109.76M	-148.24M	229K
Jun 2018	-34.91M	71.91M	6.87M
Sep 2018	-61.43M	46.90M	2.98M

LOXO cash flow history

Loxo Oncology
Insider Trading

Loxo Oncology Inc. (NASDAQ:LOXO): Insider trades (number of shares)
Period	Buy	Sel
Jan 2018	0	34582
Feb 2018	0	19782
Mar 2018	0	23023
Apr 2018	0	26482
May 2018	0	28823
Jun 2018	0	193680
Jul 2018	0	1421123
Aug 2018	0	43750
Sep 2018	0	37000
Oct 2018	0	39095
Nov 2018	0	33750
Dec 2018	725	37250

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	13 Dec 2018	NAIDER AVI Z. director director	Common Stock	725	N/A	N/A
Option	11 Dec 2018	VAN NAARDEN JACOB officer: Chief Operating Officer officer: Chief Operating Officer	Employee Stock Option (Right to Buy)	11,500	$8.66	$99,579
Option	11 Dec 2018	VAN NAARDEN JACOB officer: Chief Operating Officer officer: Chief Operating Officer	Common Stock	11,500	$8.66	$99,579
Option	11 Dec 2018	BURSTEIN JENNIFER officer: Senior VP of Finance officer: Senior VP of Finance	Employee Stock Option (Right to Buy)	1,250	N/A	N/A
Sale	11 Dec 2018	BURSTEIN JENNIFER officer: Senior VP of Finance officer: Senior VP of Finance	Common Stock	1,250	N/A	N/A
Option	11 Dec 2018	BURSTEIN JENNIFER officer: Senior VP of Finance officer: Senior VP of Finance	Common Stock	1,250	N/A	N/A
Option	11 Dec 2018	VAN NAARDEN JACOB officer: Chief Operating Officer officer: Chief Operating Officer	Employee Stock Option (Right to Buy)	11,500	N/A	N/A
Option	11 Dec 2018	VAN NAARDEN JACOB officer: Chief Operating Officer officer: Chief Operating Officer	Common Stock	11,500	N/A	N/A
Sale	11 Dec 2018	VAN NAARDEN JACOB officer: Chief Operating Officer officer: Chief Operating Officer	Common Stock	4,500	N/A	N/A
Option	11 Dec 2018	BILENKER JOSHUA H. director, officer: President & CEO director, officer: President & ..	Employee Stock Option (Right to Buy)	10,000	N/A	N/A

LOXO insider trading transactions

Loxo Oncology
Patents

Status	Patent	Filling date	Issue date
Application	Application FORMULATIONS OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6- -DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CAR- BONITRILE Filling date: 21 Jan 2022 Issue date: 30 Jun 2022	21 Jan 2022	30 Jun 2022
Application	Application METHODS OF DIAGNOSING AND TREATING CANCER Filling date: 23 Nov 2021 Issue date: 24 Mar 2022	23 Nov 2021	24 Mar 2022
Application	Application FORMULATIONS OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6- -DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CAR- BONITRILE Filling date: 18 Nov 2021 Issue date: 24 Mar 2022	18 Nov 2021	24 Mar 2022
Application	Application COMPOUNDS USEFUL AS KINASE INHIBITORS Filling date: 12 Nov 2021 Issue date: 3 Mar 2022	12 Nov 2021	3 Mar 2022
Grant	Grant Utility: Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrim- idin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof Filling date: 18 May 2017 Issue date: 4 Jan 2022	18 May 2017	4 Jan 2022
Application	Application PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6- -DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CAR- BONITRILE Filling date: 13 Aug 2021 Issue date: 9 Dec 2021	13 Aug 2021	9 Dec 2021
Grant	Grant Utility: Methods of treating pediatric cancers Filling date: 10 Jan 2020 Issue date: 7 Dec 2021	10 Jan 2020	7 Dec 2021
Application	Application SPRAY-DRIED DISPERSIONS, FORMULATIONS, AND POLYMORPHS OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TR- IFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE Filling date: 29 Jul 2019 Issue date: 28 Oct 2021	29 Jul 2019	28 Oct 2021
Grant	Grant Utility: Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6- -diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-car- bontrile Filling date: 16 Jun 2020 Issue date: 24 Aug 2021	16 Jun 2020	24 Aug 2021
Grant	Grant Utility: Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof Filling date: 26 Oct 2017 Issue date: 17 Aug 2021	26 Oct 2017	17 Aug 2021

LOXO patents

Frequently Asked Questions (FAQ)

What's the price of Loxo Oncology stock today?

One share of Loxo Oncology stock can currently be purchased for approximately $234.76.
When is Loxo Oncology's next earnings date?

Unfortunately, Loxo Oncology's (LOXO) next earnings date is currently unknown.
Does Loxo Oncology pay dividends?

No, Loxo Oncology does not pay dividends.
How much money does Loxo Oncology make?

Loxo Oncology has a market capitalization of 6.57B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 351.28% to 3.52M US dollars.
What is Loxo Oncology's stock symbol?

Loxo Oncology Inc. is traded on the NASDAQ under the ticker symbol "LOXO".
What is Loxo Oncology's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Loxo Oncology?

Shares of Loxo Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
What is Loxo Oncology's official website?

The official website for Loxo Oncology is loxooncology.com.